Diyabeti Öngörmede Serum Miyonektin ve Adropin Düzeyleri

Year 2023, Volume: 3 Issue: 2, 129 - 136, 11.08.2023

Emel Sağlam , Emre Durcan , İsmail Dağ , Mustafa Dinç

https://doi.org/10.58252/artukluder.1243870

Abstract

Giriş: Miyonektin insülin direnci (IR) ve tip 2 diyabetes mellitus (T2DM) ile ilişkili bir miyokin iken adropin, IR'yi ve bozulmuş glukoz toleransını (BGT) önleyen bir peptit hormondur. Adropin karaciğer tarafından üretilir ve enerji homeostazını düzenler. Çalışmamızda yeni tanı almış-tedavisiz- tip 2 diyabetes mellitus (nT2DM), prediyabet ve sağlıklı kontrollerde serum miyonektin ve adropin düzeylerinin değerlendirilmesi amaçlanmıştır.
Yöntem: Çalışmamızda toplam 167 kişi OGTT ve HbA1c bakılarak 3 alt gruba ayrıldı; 61 prediyabet (%36.5), 62 nT2DM (%37.1), 44 kontrol (%26.3). Serum miyonektin ve adropin seviyeleri, ELISA kitleri kullanılarak test edildi. Katılımcıların antropometrik (yaş, cinsiyet, kilo, boy, bel çevresi, kalça çevresi, bel/kalça oranı, vücut kitle indeksi) ve biyokimyasal bulguları tüm gruplar arasında değerlendirildi.
Bulgular: Çalışmamız nT2DM ve bel/kalça oranının miyonektin düzeylerini etkileyebileceğini gösterdi (p = 0.028 ve p = 0.015; sırasıyla). Prediyabet grubunda, miyonektin değeri ile sistolik kan basıncı değeri arasında anlamlı bir korelasyon saptandı (p = 0.017). Grupların ortalama miyonektin ve adropin seviyeleri arasında anlamlı fark yoktu. Lineer regresyon analizi, nT2DM'nin miyonektini etkilediğini ancak adropin değerlerini etkilemediğini ortaya koydu. Adropin düzeyleri nT2DM grubunda total kolesterol, LDL-kolesterol ve trigliserit düzeyleri ile koreleydi (p = 0.002, p = 0.004 ve p = 0.035; sırasıyla).
Sonuç: Bu çalışmadan elde edilen bulgular önceki çalışmaları desteklemektedir ve yeni tanı almış T2DM'li hastalarda serum miyonektin düzeylerinin değişebileceğini göstermiştir. Serum miyonektin seviyeleri, diyabetes mellitusu öngörmede değerli bir belirteç olabilir.

Keywords

Adropin, Diyabetes mellitus, Miyonektin, Pre-diyabet

Supporting Institution

Desteleyen kurum yoktur

Serum Myonectin and Adropin Levels in Predicting Diabetes

Abstract

Introduction: Myonectin is a myokine associated with type 2 diabetes mellitus and insulin resistance, and adropin is a peptide hormone that prevents IR and impaired glucose tolerance. Adropin is produced by the liver and regulates energy homeostasis. This research aimed to examine the serum levels of myonectin and adropin levels among prediabetes, newly-diagnosed type 2 diabetes mellitus, and healthy controls.
Methods: For this cross-sectional study, a total of 167 individuals were divided into 3 subgroups using OGTT and HbA1c; 61 prediabetes (36.5%), 62 nT2DM (37.1%), and 44 healthy controls (26.3%). Serum levels of myonectin and adropin were assayed using enzyme-linked immunoassay kits. The anthropometric (age, gender, weight, height, waist/hip ratio -WHR-, waist and hip circumference, and body mass index -BMI-) and biochemistry findings of the participants were evaluated between the groups.
Results: Our study showed that myonectin levels are associated with nT2DM and WHR (p = 0.028 and p = 0.015, respectively). The serum levels of myonectin are significantly correlated with systolic blood pressure values in the prediabetes group (p = 0.017). Linear regression analysis revealed that nT2DM affects the serum levels of myonectin, but not adropin values. The adropin levels are correlated with LDL-cholesterol, total cholesterol, and triglyceride levels in the nT2DM group (p = 0.002, p= 0.004, and p = 0.035, respectively).
Conclusion: The findings of the previous studies are supported by those of this study and indicated that the serum levels of myonectin may be associated with newly-diagnosed T2DM patients. Serum myonectin levels could be a valuable marker for predicting diabetes mellitus.

Keywords

Adropin, Diabetes mellitus, Myonectin, Prediabetes

References

• Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report ofthecommittee on theclassificationanddiagnosticcriteriaofdiabetes mellitus. Diabetes Res Clin Pract. 2002;55(1):65-85. doi: 10.1016/s0168-8227(01)00365-5
• National Institute of Diabetes and Digestive andKidneyDiseases. Insulin resistanceandpre-diabetes. Whatisprediabetes? Date: January 2023. Available from: https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance#prediabetes
• ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classificationanddiagnosisofdiabetes: Standards of Care in Diabetes—2023. Diabetes Care. 2022;46(Supplement_1):19-40. doi: 10.2337/dc23-S002
• Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933-46. doi: 10.4158/EP.14.7.933
• Seldin MM, Peterson JM, Byerly MS, Wei Z, Wong GW. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012;287(15):11968-80. doi: 10.1074/jbc.M111.336834
• Seldin MM, Lei X, Tan SY, Stanson KP, Wei Z, Wong GW. Skeletal muscle-derived myonectin activates the mammalian target of rapamycin (mTOR) pathway to suppress autophagy in liver. J Biol Chem. 2013;288(50):36073-82. doi: 10.1074/jbc.M113.500736
• Pourranjbar M, Arabnejad N, Naderipour K, Rafie F. Effectsofaerobicexercises on serum levels of myonectin and insulin resistance in obese and overweight women. J Med Life. 2018;11(4):381-6. doi: 10.25122/jml-2018-0033
• Peterson JM, Mart R, Bond CE. Effect of obesity and exercise on the expression of the novel myokines, myonectin and fibronectin type III domain containing 5. PeerJ. 2014;2:e605. doi: 10.7717/peerj.605
• Abedi B, Azarbayjani MA, Peeri M, Rasaee MJ. The effect of a single session of resistance training on serum adiponectin level and insulin resistance index in sedentary men. Journal of Arak University of Medical Sciences. 2011;14(5):53-620.
• Li K, Liao X, Wang K, Mi Q, Zhang T, Jia Y, et al. Myonectin predicts the developmentof type 2 diabetes. J Clin Endocrinol Metab. 2018;103(1):139-47. doi: 10.1210/jc.2017-01604
• Kutlu O, Altun Ö, Dikker O, Aktaş Ş, Özsoy N, Arman Y, et al. Serum adropinlevelsarereduced in adult patientswithnonalcoholicfattyliverdisease. Med Princ Pract. 2019;28(5):463-9. doi: 10.1159/000500106
• Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468-81. doi: 10.1016/j.cmet.2008.10.011
• Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes. 2014;63(10):3242-52. doi: 10.2337/db14-0388
• Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015;4(4):310-24. doi: 10.1016/j.molmet.2015.01.005
• Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O'Keeffe M, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012;97(10):3783-91. doi: 10.1210/jc.2012-2194
• Kuloglu T, Aydin S. Immunohistochemical expressions of adropin and ınducible nitric oxide synthase in renal tissues of rats with streptozotocin-induced experimental diabetes. Biotech Histochem. 2014;89(2):104-10. doi: 10.3109/10520295.2013.821713
• Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013;61(8):1161-4. doi: 10.2310/JIM.0000000000000003
• Akcilar R, Kocak FE, Simsek H, Akcilar A, Bayat Z, Ece E, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016;117(2):100-5. doi: 10.4149/bll_2016_020
• Li Z, Yang YL, Zhu YJ, Li CG, Tang YZ, Ni CL, et al. Circulating serum myonectin levels in obesity and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2021;129(7):528-34. doi: 10.1055/a-0896-8548
• Park SY, Choi JH, Ryu HS, Pak YK, Park KS, Lee HK, et al. C1q tumor necrosis factor alpha-related protein isoform 5 is increased in mitochondrial DNA-depleted myocytes and activates AMP-activated protein kinase. J Biol Chem. 2009;284(41):27780-9. doi: 10.1074/jbc.M109.005611
• Ghany R, Tamariz L, Chen G, Dawkins E, Forbes E, Tajiri T, et al. Impact of prediabetes on cardiac function among primarycare patients. Metab Syndr Relat Disord. 2022. doi: 10.1089/met.2021.0006
• Reis JP, Allen NB, Bancks MP, Carr JJ, Lewis CE, Lima JA, et al. Duration of diabetes and prediabetes during adulthood and subclinical atherosclerosis and cardiac dysfunction in middle age: The CARDIA Study. Diabetes Care. 2018;41(4):731-8. doi: 10.2337/dc17-2233
• Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-41. doi: 10.1056/NEJMoa1008862
• Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. doi: 10.1016/S0140-6736(10)60484-9
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13. doi: 10.1016/s0140-6736(02)11911-8
• Li K, Xu X, Hu W, Li M, Yang M, Wang Y, et al. Glypican-4 is increased in human subjects with impaired glucose tolerance and decreased in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2014;51(6):981-90. doi: 10.1007/s00592-014-0652-5
• Liu F, Cui B, Zhao X, Wu Y, Qin H, Guo Y, et al. Correlation of serum adropin levels with risk factors of cardiovascular disease in hemodialysis patients. Metab Syndr Relat Disord. 2021;19(7):401-8. doi: 10.1089/met.2021.0015
• He L, Zhang FJ, Li HY, Li L, Song LG, Mao Y, et al. Anti-diabetic role of adropin in streptozotocin induced diabetic rats via alteration of pi3k/akt and insulin signaling pathway. J Oleo Sci. 2021;70(5):657-64. doi: 10.5650/jos.ess21019
• Skrzypski M, Kołodziejski PA, Pruszyńska-Oszmałek E, Wojciechowicz T, Janicka P, Krążek M, et al. Daily treatment of mice with type 2 diabetes with adropin for four weeks improves glucolipid profile, reduces hepatic lipid content and restores elevated hepatic enzymes in serum. Int J Mol Sci. 2022;23(17). doi: 10.3390/ijms23179807
• Chang JB, Chu NF, Lin FH, Hsu JT, Chen PY. Relationship between plasma adropin levels and body composition and lipid characteristics amongst young adolescents in Taiwan. Obes Res Clin Pract. 2018;12(Suppl 2):101-7. doi: 10.1016/j.orcp.2017.03.001